加格列净
加格列净（分子式：C25H29ClO6，化学名：(1S)-1,5-脱水-1-C-[3-[4-[(1α,3α,5α)-双环[3.1.0]己-3-基氧基]苄基-4-氯苯基]-D-葡萄糖醇）是一种由四环医药研发的实验性SGLT2抑制剂，[1]用于治疗糖尿病。[2]
 | |
| 法律規範狀態 | |
|---|---|
| 法律規範 |
|
| 识别信息 | |
| CAS号 | 1800115-22-3  |
| UNII | |
| 化学信息 | |
| 化学式 | C25H29ClO6 |
| 摩尔质量 | 460.95 g·mol−1 |
| 3D模型（JSmol） | |
| |
它可以2-氯-5-溴苯甲酸和3-环戊烯-1-醇为原料，经多步反应制得。[3]
参考文献
- ^ Song, Ling; Yao, Xueting; Liu, Yang; Zhong, Wen; Jiang, Ji; Liu, Hongzhong; Zhou, Huimin; Shi, Chongtie; Zong, Kaiqi; Wang, Chong; Ma, Chuanxiang; Liu, Dongyang; Hu, Pei. Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods. European Journal of Pharmaceutical Sciences. April 2020, 147: 105281. doi:10.1016/j.ejps.2020.105281.
- ^ 惠升生物加格列净片. 四环医药. [2023-12-14]. （原始内容存档于2023-12-14）.
- ^ Wu, Frank. Optically pure benzyl-4-chlorophenyl-C-glucoside derivatives as SGLT inhibitors (diabetes mellitus). 2015. EP2891654.